Contacts: Investor Inquiries: Shrinal Inamdar Director, Investor Relations (604) 678-1388 ir@zymeworks.com investors@zymeworks.com Media Inquiries: Diana Papove Senior Director, Corporate Communications (604) 678-1388 ir@zymeworks.com media@zymeworks.com Zymeworks is a global clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, multifunctional biotherapeutics. Zymeworks' mission is to make a meaningful difference in the lives of people impacted by dif ...

VANCOUVER, British Columbia, July 11, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that management will report its second quarter 2024 financial results after market close on August 1, 2024. Following the announcement, management will host a conference call and webcast to discuss financial results and provid ...

Zymeworks Inc. (NASDAQ:ZYME) Q1 2024 Earnings Call Transcript May 2, 2024 4:30 PM ET Company Participants Shrinal Inamdar - Director, Investor Relations Ken Galbraith - Chair and CEO Paul Moore - Chief Scientific Officer Conference Call Participants Stephen Willey - Stifel Ashiq Mubarack - city Ivy Wang - Jefferies Brian Cheng - JPMorgan Jon Miller - Evercore ISI Operator Thank you for standing by. This is the conference operator. Welcome to Zymeworks First Quarter 2024 Results Conference Call and Webcast. ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________________________________ FORM 10-Q ______________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-41535 _________________________ ...

Zymeworks Provides Corporate Update and Reports First Quarter 2024 Financial Results Vancouver, British Columbia (May 2, 2024) – Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today reported financial results for the three months ended March 31, 2024 and provided a summary of recent business highlights. "We are very pleased to have presented five pos ...

| --- | --- | --- | --- | --- | |-------|-----------------------------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | | 4Q & FY 2023 Results | | | | | | Conference Call and Webcast | | | | | | | | | | Forward-Looking Statements This presentation and the accompanying oral commentary include "forward-looking statements" or information within the meaning of the applicable securities legislation, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities E ...

Zymeworks Inc. (NASDAQ:ZYME) Q4 2023 Earnings Conference Call March 6, 2024 4:30 PM ET Company Participants Shrinal Inamdar - Director, Investor Relations Dr. Chris Astle - Senior Vice President and CFO Paul Moore - Chief Scientific Officer Ken Galbraith - Chair and CEO Conference Call Participants Stephen Willey - Stifel Ivy Wang - Jefferies Yigal Nochomovitz - Citigroup Brian Cheng - JPMorgan Jon Miller - Evercore ISI Operator Thank you for standing by. This is the conference operator. Welcome to Zymework ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _________________________ FORM 10-K _________________________ (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________to ___________ Commission file number: 001-41535 _________________________ ZYMEWOR ...

| --- | --- | --- | --- | --- | |-------|-----------------------------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | | Third Quarter 2023 Results | | | | | | Conference Call and Webcast | | | | | | | | | | Forward-Looking Statements This presentation and the accompanying oral commentary include "forward-looking statements" or information within the meaning of the applicable securities legislation, including Section 27A of the Securities Act of 1933, as amended, and Section 21E o ...

Financial Data and Key Metrics Changes - For the nine months ended September 30, 2023, Zymeworks reported a net loss of $104.2 million, or $1.53 per diluted share, a 44% decrease from a net loss of $185.1 million for the same period in 2022 [8][9] - Revenue for the nine months ended September 30, 2023, was $59.1 million, compared to $10 million for the same period in 2022, primarily driven by $56.3 million from collaboration with Jazz [9][10] - Research and development expenses decreased to $118.1 million from $155.6 million in the same period in 2022, with a non-GAAP decrease of $31.4 million [10][11] - General and administrative expenses increased to $55.6 million from $43.2 million in the same period in 2022 [13][14] - Cash resources were $390.2 million as of September 30, 2023, a net reduction of $102 million from December 31, 2022 [15] Business Line Data and Key Metrics Changes - The decrease in research and development expenses was attributed to the transfer of the zanidatamab program to Jazz, while preclinical expenses for ZW171 and ZW191 increased [11][12] - The company reduced its employee headcount by approximately 45% over the past 21 months, from 455 to 252 full-time employees [15] Market Data and Key Metrics Changes - The company expects to have cash resources to fund operations through at least the end of 2026, potentially beyond, due to non-dilutive inflows from licensing and collaboration agreements [19][64] Company Strategy and Development Direction - Zymeworks is focused on developing therapies for difficult-to-treat cancers, with a pipeline strategy termed "5 by 5," aiming to nominate five clinical trials and five new molecules by 2027 [30][32] - The latest IND candidate, ZW251, targets GPC3 for hepatocellular carcinoma, addressing a significant unmet need in liver cancer treatment [37][39] - The company is exploring the potential for ADCs and multi-specific antibodies to be used in combination with standard care therapies [35][36] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the potential for zanidatamab to become a standard of care in first-line GEA patients, with upcoming pivotal data expected in 2024 [65][66] - The company is optimistic about the commercial opportunities for zanidatamab based on recent data and ongoing studies [86][88] Other Important Information - The company has secured a new office facility in Bellevue, Washington, to accommodate its remaining workforce after vacating its Seattle office [18] - Zymeworks is strategically planning for a longer-term R&D strategy beyond the current 5 by 5 pipeline [62][64] Q&A Session Summary Question: What are the opportunities for the GPC3 ADC relative to other modalities? - Management highlighted that Zymeworks is focusing on ADCs for GPC3, which differentiates their strategy from others exploring CAR T and other approaches [69][70] Question: What factors could extend the cash runway beyond 2026? - Management indicated that the current cash runway extends beyond 2026 without new partnerships, but additional collaborations could further enhance financial flexibility [72][73] Question: What types of combinations are being considered for the GPC3 ADC? - The company is considering combinations with standard of care therapies to maximize patient response rates and durability [76][78] Question: What is the status of IND enabling studies for leading preclinical assets? - Management confirmed that both ZW171 and ZW191 are on target for IND submissions in 2024, with further guidance expected next year [80][81] Question: How does the KEYNOTE-811 data impact the outlook for zanidatamab? - Management expressed optimism about zanidatamab's commercial opportunity based on recent data, indicating a stronger position than previously anticipated [86][88]